1001 - 1010 of 6284 Results
Title
Year
-
OPENTitle: Glucagon‐like Peptides (GLP‐1) Perspectives in Synucleinopathies TreatmentJournal Name: Movement Disorders Clinical PracticePublisher: WileyVol: 5Issue #: 3Start Page: 255End Page: 258Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1002/mdc3.12611Best OA location URL: https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/mdc3.12611Citation Count: 7
- Genomewide association study of Parkinson's disease clinical biomarkers in 12 longitudinal patients' cohorts2019OPENTitle: Genomewide association study of Parkinson's disease clinical biomarkers in 12 longitudinal patients' cohortsJournal Name: Movement DisordersPublisher: WileyVol: 34Issue #: 12Start Page: 1839End Page: 1850Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1002/mds.27845Best OA location URL: http://hdl.handle.net/20.500.11820/51a559a5-38a4-4a09-a501-6c78ddefb3fdCitation Count: 164
- Unique Astrocyte Cytoskeletal and Nuclear Morphology in a Three-Dimensional Tissue-Engineered Rostral Migratory Stream2022OPENTitle: Unique Astrocyte Cytoskeletal and Nuclear Morphology in a Three-Dimensional Tissue-Engineered Rostral Migratory StreamJournal Name: NeurogliaPublisher: MDPI AGVol: 3Issue #: 1Start Page: 41End Page: 60Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.3390/neuroglia3010003Best OA location URL: https://www.mdpi.com/2571-6980/3/1/3/pdf?version=1646557010Citation Count: 5
- The use of angiotensin-converting enzyme inhibitors vs. angiotensin receptor blockers and cognitive decline in Alzheimer’s disease: the importance of blood-brain barrier penetration and APOE ε4 carrier status2021OPENTitle: The use of angiotensin-converting enzyme inhibitors vs. angiotensin receptor blockers and cognitive decline in Alzheimer’s disease: the importance of blood-brain barrier penetration and APOE ε4 carrier statusJournal Name: Alzheimer's Research & TherapyPublisher: Springer Science and Business Media LLCVol: 13Issue #: 1Start Page:End Page:Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.1186/s13195-021-00778-8Best OA location URL: https://alzres.biomedcentral.com/track/pdf/10.1186/s13195-021-00778-8Citation Count: 54
- Seeding selectivity and ultrasensitive detection of tau aggregate conformers of Alzheimer disease2018OPENTitle: Seeding selectivity and ultrasensitive detection of tau aggregate conformers of Alzheimer diseaseJournal Name: Acta NeuropathologicaPublisher: Springer Science and Business Media LLCVol: 137Issue #: 4Start Page: 585End Page: 598Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.1007/s00401-018-1947-3Best OA location URL: https://link.springer.com/content/pdf/10.1007/s00401-018-1947-3.pdfCitation Count: 119
- Association of DRD2 and DRD3 polymorphisms with Parkinson's disease in a multiethnic consortium2011OPENTitle: Association of DRD2 and DRD3 polymorphisms with Parkinson's disease in a multiethnic consortiumJournal Name: Journal of the Neurological SciencesPublisher: Elsevier BVVol: 307Issue #: 1-2Start Page: 22End Page: 29Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1016/j.jns.2011.05.031Best OA location URL: https://www.ncbi.nlm.nih.gov/pmc/articles/3155471Citation Count: 56
- The 5‐HT2A/2C inverse agonist nelotanserin alleviates L‐DOPA‐induced dyskinesia in the MPTP‐lesioned marmoset2023OPENTitle: The 5‐HT2A/2C inverse agonist nelotanserin alleviates L‐DOPA‐induced dyskinesia in the MPTP‐lesioned marmosetJournal Name: European Journal of NeurosciencePublisher: WileyVol: 59Issue #: 6Start Page: 1169End Page: 1176Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.1111/ejn.16104Best OA location URL: https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/ejn.16104Citation Count: 3
- Breakthrough News in Adenoviral Vector‐Mediated AADC Gene Therapy: Lessons from the Success in AADC Deficiency and Possible Future Applications2022OPENTitle: Breakthrough News in Adenoviral Vector‐Mediated AADC Gene Therapy: Lessons from the Success in AADC Deficiency and Possible Future ApplicationsJournal Name: Movement Disorders Clinical PracticePublisher: WileyVol: 9Issue #: 6Start Page: 737End Page: 738Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1002/mdc3.13503Best OA location URL: https://www.ncbi.nlm.nih.gov/pmc/articles/9346230Citation Count: 1
-
OPENTitle: GP2: The Global Parkinson's Genetics ProgramJournal Name: Movement DisordersPublisher: WileyVol: 36Issue #: 4Start Page: 842End Page: 851Publication Date:Open Access(OA) Status: OPENLicense: cc-by, cc-byDOI - Digital Object Identifier: 10.1002/mds.28494Best OA location URL: https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/mds.28494Citation Count: 129
-
OPENTitle: Proteome profiling of cerebrospinal fluid reveals biomarker candidates for Parkinson’s diseaseJournal Name: Cell Reports MedicinePublisher: Elsevier BVVol: 3Issue #: 6Start Page: 100661End Page: 100661Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.1016/j.xcrm.2022.100661Best OA location URL: https://doi.org/10.1016/j.xcrm.2022.100661Citation Count: 124